Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1993:45 Suppl 1:S17-20; discussion S43-4.
doi: 10.1007/BF01844198.

Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils

Affiliations
Comparative Study

Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils

G Marone et al. Eur J Clin Pharmacol. 1993.

Abstract

Pro-inflammatory and vasoactive mediators released from human basophils and mast cells play a role in several inflammatory and immune disorders. It was recently demonstrated that cyclosporin A (CsA) exerts anti-inflammatory effects by inhibiting the release of preformed and de novo synthesized mediators from human basophils. This study compared the effects of pharmacological concentrations of deflazacort (DFZ) and prednisolone (PRED) on the anti-IgE-mediated release of preformed (histamine) and de novo synthesized (leukotriene C4: [LTC4]) mediators from basophils. Basophils were cultured for 18 hours in the presence of pharmacological concentrations of DFZ (10(-8) to 3 x 10(-6) M). DFZ inhibited the anti-IgE-mediated release of histamine and LTC4 from basophils in a concentration-dependent manner (6-40%), and had a similar efficacy and potency to PRED. The effect of DFZ (10(-8) to 10(-7) M) in combination with CsA on the immunological release of histamine and LTC4 from basophils was also evaluated. An 18-hour incubation of basophils with DFZ (10(-8) M) followed by a short (15-minute) incubation with CsA (30 ng/ml) resulted in an additive inhibition of the release of histamine and LTC4. The additive anti-inflammatory effect of these drugs makes them interesting candidates for future controlled clinical trials in inflammatory diseases in which basophil-derived mediators play a relevant role.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Int Arch Allergy Appl Immunol. 1985;77(1-2):241-3 - PubMed
    1. Am Rev Respir Dis. 1990 Nov;142(5):1108-11 - PubMed
    1. Am J Ophthalmol. 1990 Dec 15;110(6):641-5 - PubMed
    1. Lancet. 1992 Feb 8;339(8789):324-8 - PubMed
    1. Am Rev Respir Dis. 1989 Jun;139(6):1375-82 - PubMed

Publication types

MeSH terms

LinkOut - more resources